Praxis Precision Medicines, Inc. PRAX Vormatrigine — Program-specific expenses

Other product segments

Similar metrics at other companies

HGVMarketing expense — Expenses

$239M+3.9%

HGVRental expense — Expenses

$204M+4.6%

HGVSelling expense — Expenses

$181M-7.2%

HGVClub expense — Expenses

$22M+10.0%

HGVLicense fee expense — Expenses

$53M+8.2%

HGVProperty management expense — Expenses

$37M+8.8%

FAQ

What is Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses?

Praxis Precision Medicines, Inc. (PRAX) reported vormatrigine — program-specific expenses of $12.88M in Q2 2026.

How has Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses changed year-over-year?

Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses decreased by 28.3% year-over-year, from $17.96M to $12.88M.

What is the long-term trend for Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses?

Over 2 years (2023 to 2025), Praxis Precision Medicines, Inc.'s vormatrigine — program-specific expenses has grown at a 243.5% compound annual growth rate (CAGR), from $6.28M to $74.06M.

What does vormatrigine — program-specific expenses mean?

This metric represents the direct costs associated with the development, production, and commercialization activities for the Vormatrigine therapeutic program. It captures the specific financial resources allocated to clinical trials, manufacturing, and supply chain operations dedicated to this asset. Monitoring these expenses provides insight into the capital intensity and operational progress of the company's key pipeline candidates.